• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Uganda Pharmaceuticals and Healthcare Report Q2 2012

  • ID: 2093642
  • February 2012
  • Region: Uganda
  • 32 Pages
  • Business Monitor International

Business Monitor International's Uganda Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Uganda's pharmaceuticals and healthcare industry.

BMI View: Uganda's pharmaceutical market is typical of developing markets: defined by an absence of a clear regulatory framework, a dependence upon drug imports and low healthcare expenditure per capita. Economic growth will aid the development of Uganda's pharmaceutical and healthcare sectors as affordability levels increase and fiscal contributions towards healthcare service provision rise – providing revenue earning opportunities for companies investing in the sector.

Headline Expenditure Projections

Pharmaceuticals: UGX676bn (US$266mn) in 2011 to UGX750bn (US$296mn) in 2012; +11.0% growth in local currency terms and +11.1%.

Healthcare: UGX2,845bn (US$1.12bn) in 2011 to UGX3,278bn (US$1.29bn) in 2012; 15.2% growth in local currency terms.

Risk/Reward Ratings: In BMI's Q212 BERs, Uganda is ranked 26th in the Middle READ MORE >

Note: Product cover images may vary from those shown

Pharmaceutical Risk/Reward Ratings

Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q212

Market Summary
Regulatory Regime
Intellectual Property Issues
Industry Forecast Scenario
Pharmaceutical Market Forecast

Table: Pharmaceutical Sales Indicators 2008-2016

Healthcare Market Forecast
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016

Macroeconomic Outlook

Table: Uganda – Economic Activity


BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings

Risk/Reward Ratings Methodology

Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S